These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 18311541

  • 1. The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpura.
    Pasa S, Altintas A, Cil T, Danis R, Ayyildiz O.
    J Thromb Thrombolysis; 2009 Apr; 27(3):329-33. PubMed ID: 18311541
    [Abstract] [Full Text] [Related]

  • 2. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study.
    Godeau B, Porcher R, Fain O, Lefrère F, Fenaux P, Cheze S, Vekhoff A, Chauveheid MP, Stirnemann J, Galicier L, Bourgeois E, Haiat S, Varet B, Leporrier M, Papo T, Khellaf M, Michel M, Bierling P.
    Blood; 2008 Aug 15; 112(4):999-1004. PubMed ID: 18463354
    [Abstract] [Full Text] [Related]

  • 3. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC.
    Am J Hematol; 2005 Apr 15; 78(4):275-80. PubMed ID: 15795920
    [Abstract] [Full Text] [Related]

  • 4. Retrospective analysis of rituximab therapy and splenectomy in childhood chronic and refractory immune thrombocytopenic purpura.
    Ay Y, Karapinar TH, Oymak Y, Toret E, Demirag B, Ince D, Ozcan E, Moueminoglou N, Koker SA, Vergin C.
    Blood Coagul Fibrinolysis; 2016 Jun 15; 27(4):431-5. PubMed ID: 26656905
    [Abstract] [Full Text] [Related]

  • 5. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.
    Stasi R, Pagano A, Stipa E, Amadori S.
    Blood; 2001 Aug 15; 98(4):952-7. PubMed ID: 11493438
    [Abstract] [Full Text] [Related]

  • 6. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.
    Chouhan JD, Herrington JD.
    Pharmacotherapy; 2010 Jul 15; 30(7):666-83. PubMed ID: 20575632
    [Abstract] [Full Text] [Related]

  • 7. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
    Koulova L, Alexandrescu D, Dutcher JP, O'Boyle KP, Eapen S, Wiernik PH.
    Am J Hematol; 2005 Jan 15; 78(1):49-54. PubMed ID: 15609292
    [Abstract] [Full Text] [Related]

  • 8. Treatment of a patient with chronic immune thrombocytopenic purpura with rituximab and monitoring by flow cytometric analysis.
    Thude H, Gruhn B, Werner U, Schorner U, Häfer R, Zintl F, Barz D.
    Acta Haematol; 2004 Jan 15; 111(4):221-4. PubMed ID: 15153715
    [Abstract] [Full Text] [Related]

  • 9. Is splenectomy necessary for immune thrombocytopenic purpura? The role of rituximab in patients with corticosteroid resistance in a single-center experience.
    Zhang C, Liu HF, Chen XH, Gao L, Gao L, Liu Y, Kong PY, Sun AH, Zhang X.
    Clin Ther; 2014 Mar 01; 36(3):385-8. PubMed ID: 24594069
    [Abstract] [Full Text] [Related]

  • 10. Rituximab in immune thrombocytopenia: transient responses, low rate of sustained remissions and poor response to further therapy in refractory patients.
    Aleem A, Alaskar AS, Algahtani F, Rather M, Almahayni MH, Al-Momen A.
    Int J Hematol; 2010 Sep 01; 92(2):283-8. PubMed ID: 20640541
    [Abstract] [Full Text] [Related]

  • 11. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
    Schweizer C, Reu FJ, Ho AD, Hensel M.
    Ann Hematol; 2007 Oct 01; 86(10):711-7. PubMed ID: 17622529
    [Abstract] [Full Text] [Related]

  • 12. Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab.
    Zaja F, Marin L, Chiozzotto M, Puglisi S, Volpetti S, Fanin R.
    Am J Hematol; 2012 Mar 01; 87(3):321-3. PubMed ID: 22190262
    [Abstract] [Full Text] [Related]

  • 13. Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment.
    Parodi E, Nobili B, Perrotta S, Rosaria Matarese SM, Russo G, Licciardello M, Zecca M, Locatelli F, Cesaro S, Bisogno G, Giordano P, De Mattia D, Ramenghia U.
    Int J Hematol; 2006 Jul 01; 84(1):48-53. PubMed ID: 16867902
    [Abstract] [Full Text] [Related]

  • 14. Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura.
    Zhou Z, Yang R.
    Crit Rev Oncol Hematol; 2008 Jan 01; 65(1):21-31. PubMed ID: 17681784
    [Abstract] [Full Text] [Related]

  • 15. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study.
    Giagounidis AA, Anhuf J, Schneider P, Germing U, Söhngen D, Quabeck K, Aul C.
    Eur J Haematol; 2002 Aug 01; 69(2):95-100. PubMed ID: 12366712
    [Abstract] [Full Text] [Related]

  • 16. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.
    Peñalver FJ, Jiménez-Yuste V, Almagro M, Alvarez-Larrán A, Rodríguez L, Casado M, Gallur L, Giraldo P, Hernández R, Menor D, Rodríguez MJ, Caballero D, González R, Mayans J, Millán I, Cabrera JR, Multi-institutional Retrospective Spanish Study Group on the Use of Rituximab in Refractory ITP.
    Ann Hematol; 2006 Jun 01; 85(6):400-6. PubMed ID: 16550390
    [Abstract] [Full Text] [Related]

  • 17. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis.
    Garcia-Chavez J, Majluf-Cruz A, Montiel-Cervantes L, Esparza MG, Vela-Ojeda J, Mexican Hematology Study Group.
    Ann Hematol; 2007 Dec 01; 86(12):871-7. PubMed ID: 17874322
    [Abstract] [Full Text] [Related]

  • 18. Recent advances in the treatment of chronic refractory immune thrombocytopenic purpura.
    Kojouri K, George JN.
    Int J Hematol; 2005 Feb 01; 81(2):119-25. PubMed ID: 15765779
    [Abstract] [Full Text] [Related]

  • 19. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia.
    Zaja F, Baccarani M, Mazza P, Bocchia M, Gugliotta L, Zaccaria A, Vianelli N, Defina M, Tieghi A, Amadori S, Campagna S, Ferrara F, Angelucci E, Usala E, Cantoni S, Visani G, Fornaro A, Rizzi R, De Stefano V, Casulli F, Battista ML, Isola M, Soldano F, Gamba E, Fanin R.
    Blood; 2010 Apr 08; 115(14):2755-62. PubMed ID: 20130241
    [Abstract] [Full Text] [Related]

  • 20. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome.
    Shanafelt TD, Madueme HL, Wolf RC, Tefferi A.
    Mayo Clin Proc; 2003 Nov 08; 78(11):1340-6. PubMed ID: 14601692
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.